| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
|
Purity: ≥98%
CCT251921 is a novel, potent, selective, and orally bioavailable small-molecule inhibitor of CDK8 and CDK19 (IC50 =2.3 nM; CDK19 = 2.6 nM). CCT251921 showed the optimal compromise of in vitro bioactive compound, pharmacokinetic, and physicochemical properties and is suitable for progression to animal models of cancer. The Mediator complex-associated cyclin-dependent kinase CDK8 has been implicated in human disease, particularly in colorectal cancer where it has been reported as a putative oncogene.
| ln Vitro |
Tested on a panel of 279 kinases, 55 receptors, ion channels, and enzymes at 1 μM, CCT-251921 has an acceptable water solubility and minimal activity; weak inhibition of CYP was seen. In human cancer cell lines with constitutively activated WNT pathway signaling, such as LS174T (β-catenin mutant), SW480, Colo205 (APC mutant), or PA-1 human teratocarcinoma WNT ligand-dependent cells, CCT-251921 exhibits potent inhibition of reporter gene-based readouts measuring basal WNT pathway activity [1].
|
|---|---|
| ln Vivo |
For the purpose of advancing preclinical efficacy and safety investigations as well as facilitating additional assessment of CDK8/19 pharmacology, CCT-251921 shows enhanced oral pharmacokinetics and pharmacological characteristics. CCT-251921 therapy decreased mouse tumor weight (54.2%) at day 15 in an APC mutant SW620 human colorectal cancer xenograft model. After the last dosage, STAT1SER727 phosphorylation inhibition lasts for longer than six hours [1].
|
| References |
| Molecular Formula |
C21H23CLN6O
|
|---|---|
| Molecular Weight |
410.8999
|
| Exact Mass |
410.162
|
| CAS # |
1607837-31-9
|
| PubChem CID |
74222277
|
| Appearance |
White to off-white solid powder
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
696.4±55.0 °C at 760 mmHg
|
| Flash Point |
375.0±31.5 °C
|
| Vapour Pressure |
0.0±2.2 mmHg at 25°C
|
| Index of Refraction |
1.757
|
| LogP |
2.78
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
29
|
| Complexity |
626
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
VPJXPDLMACOGIZ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C21H23ClN6O/c1-27-16-3-2-13(10-14(16)11-26-27)15-12-25-19(23)17(22)18(15)28-8-5-21(6-9-28)4-7-24-20(21)29/h2-3,10-12H,4-9H2,1H3,(H2,23,25)(H,24,29)
|
| Chemical Name |
8-(2-amino-3-chloro-5-(1-methyl-1H-indazol-5-yl)pyridin-4-yl)-2,8-diazaspiro[4.5]decan-1-one
|
| Synonyms |
CCT251921 CCT-251921 CCT 251921
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~25 mg/mL (~60.84 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.08 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.08 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (6.08 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4337 mL | 12.1684 mL | 24.3368 mL | |
| 5 mM | 0.4867 mL | 2.4337 mL | 4.8674 mL | |
| 10 mM | 0.2434 mL | 1.2168 mL | 2.4337 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA